Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective: An open study

Dermatology

Volumn 207, Issue 1, 2003, Pages 37-42

  Thaçi, Diamant ^a   Steinmeyer, Katrin ^a   Ebelin, Marie Eve ^b   Scott, Graham ^c   Kaufmann, Roland ^a  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Chronic hand dermatitis; Elidel; Pimecrolimus; SDZ ASM 981

Indexed keywords

PIMECROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DERMATITIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAND DISEASE; HAND PALM; HUMAN; MALE; MEDICAL ASSESSMENT; PHYSICAL DISEASE BY BODY FUNCTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; SELF EVALUATION; SKIN BURNING SENSATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; BIOLOGICAL AVAILABILITY; CHRONIC DISEASE; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HAND DERMATOSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OINTMENTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 0037634522     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070939     Document Type: Article

References (20)

1. Friedmann PS: Allergy and the skin. 2. Contact and atopic eczema. BMJ 1998;316:1226-1229.
2. Marks R: Adverse side effects from the use of topical corticosteroids; in Maibach HI, Surber C (eds): Topical Corticosteroids. Basel, Karger, 1992, pp 170-183.
3. Robertson DB, Maibach HI: Adverse systemic effects of topical corticosteroids; in Maibach HI, Surber C (eds): Topical Corticosteroids. Basel, Karger, 1992, pp 163-169.
4. Sillevis Smitt JH, Winterberg DH: Topical cor-ticosteroids in children: Local and systemic effects; in Maibach HI, Surber C (eds): Topical Corticosteroids. Basel, Karger, 1992, pp 196-209.
5. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology. Br J Dermatol 1999;141:264-273.
6. Paul C, Graeber M, Stuetz A: Ascomycins: Promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs 2000;9:69-77.
7. Meingassner J, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stütz A: A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology. Br J Dermatol 1997;137: 568-576.
8. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks: A randomised, double-blind controlled study. Br J Dermatol 2001;144:507-513.
9. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M: Safety and efficacy of pimecroli-mus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504.
10. Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Jünger M, Bräutigam M, for the CASM-DE-01 Study Group: Pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology 2002;205:271-277.
11. Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC, Gulliver W, Paul C, Molloy S, Barbier N, Thurston M, de Prost Y: Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-284.
12. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2.
13. Hebert AA, Warken KA, Cherill R: Pimecrolimus cream 1%: A new development in nonsteroid topical treatment of inflammatory skin diseases. Semin Cutan Med Surg 2001;20:260-267.
14. Stuetz A, Grassberger M, Meingassner JG: Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001;20:233-241.
15. Cherill R, Tofte S, MacNaul R, Maher T, Graeber M, Meyer K, Hanifin J: SDZ ASM 981 1% cream is effective in the treatment of chronic hand dermatitis. J Eur Acad Dermatol Venereol 2000;14(suppl 1):128.
16. Billich A, Aschauer H: Pimecrolimus (SDZ ASM 981) permeates less through skin than topical corticosteroids. Arch Dermatol Venereol 2002;129:1S693.
17. Van Leent EJ, Ebelin M-E, Burtin P, Dorobek B, Spuls PI, Bos JD: Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002;204:63-68.
18. Allen BR, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, Cardno M, Ebelin M-E, Burtin P, Stephenson TJ: Systemic exposure, tolerability and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003, in press.
19. Harper J, Lakhanpaul M, Wahn U, Pariser D, Gottlieb AB, Kaufmann R, Eichenfield L, Langley R, Scott G, Ebelin M-E, Burtin P: Pimecrolimus (Elidel®, SDZ ASM 981) cream 1% blood levels are consistently low in children with extensive atopic dermatitis. J Eur Acad Dermatol Venereol 2001;15(suppl 2):109-110.
20. Zhai H, Maibach HI: Effects of skin occlusion on percutaneous absorption: An overview. Skin Pharmacol Appl Skin Physiol 2001;14:1-10.